Pages that link to "Q35058918"
Jump to navigation
Jump to search
The following pages link to Bispecific antibody conjugates in therapeutics (Q35058918):
Displaying 24 items.
- Application of the Fc fusion format to generate tag-free bi-specific diabodies (Q33518858) (← links)
- Recruiting cytotoxic T cells to folate-receptor-positive cancer cells (Q33576953) (← links)
- Highly enhanced cytotoxicity of a dimeric bispecific diabody, the hEx3 tetrabody (Q33966998) (← links)
- Cytotoxic enhancement of a bispecific diabody by format conversion to tandem single-chain variable fragment (taFv): the case of the hEx3 diabody (Q34503084) (← links)
- Retargeting T cells for HER2-positive tumor killing by a bispecific Fv-Fc antibody (Q35005791) (← links)
- Recombinant approaches to IgG-like bispecific antibodies (Q36139512) (← links)
- Retargeting T cells and immune effector cells with bispecific antibodies (Q36234899) (← links)
- FLT3 antibody-based therapeutics for leukemia therapy (Q36251188) (← links)
- Targeting T cells with bispecific antibodies for cancer therapy (Q37220742) (← links)
- Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future (Q38074885) (← links)
- Development and prospects for bispecific antibody-based therapeutics in cancer and other applications (Q38090680) (← links)
- Construction and humanization of a functional bispecific EGFR × CD16 diabody using a refolding system (Q39445052) (← links)
- The application of mathematical modelling to the design of bispecific monoclonal antibodies (Q39972825) (← links)
- Engineering and characterization of a bispecific HER2 x EGFR-binding affibody molecule (Q39974009) (← links)
- Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells (Q40103814) (← links)
- A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. (Q40448458) (← links)
- Anti-Viral Drugs for Human Adenoviruses. (Q46103262) (← links)
- SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies (Q46702724) (← links)
- Development of cell-penetrating bispecific antibodies targeting the N-terminal domain of androgen receptor for prostate cancer therapy. (Q47307286) (← links)
- New magic bullets can hit more than one target (Q47424609) (← links)
- Use of SpyTag/SpyCatcher to construct bispecific antibodies that target two epitopes of a single antigen. (Q47997819) (← links)
- Efficient inhibition of multidrug-resistant human tumors with a recombinant bispecific anti-P-glycoprotein x anti-CD3 diabody. (Q51021559) (← links)
- [Target therapy with monoclonal antibodies] (Q73580201) (← links)
- Build-up functionalization of anti-EGFR × anti-CD3 bispecific diabodies by integrating high-affinity mutants and functional molecular formats (Q90438929) (← links)